Mucosal meningococcal vaccines

Details Mucosal meningococcal vaccines Mucosal meningococcal vaccines

A - Human Necessities

61

K

A61K 39/385 (2006.01) A61K 39/02 (2006.01) A61K 39/09 (2006.01) A61K 39/095 (2006.01) A61K 39/102 (2006.01)

Patent

CA 2514330

The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N.meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N.meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Thl/Th2 bias of the responses.

L'invention concerne des compositions immunogènes en vue d'une administration muqueuse comprenant des sacharrides capsulaires provenant au moins de deux des sérogroupes A, C, W135 et Y de N.meningitidis. Les sacharrides capsulaires contenus dans les compositions de cette invention sont, de préférence, conjugués à une (des) protéine(s) porteuse(s) et/ou sont des oligosaccharides. On retient de préférence des antigènes d'oligosaccharides conjugués. L'invention concerne également des compositions immunogènes comprenant (a) un antigène de saccharide capsulaire provenant du sérogroupe C de N.meningitidis, et (b) un adjuvant de chitosane. La composition renferme de préférence (c) un ou plusieurs antigènes et/ou des un ou plusieurs adjuvants. Les compositions se prêtent particulièrement à une administration muqueuse, y compris l'administration intranasale. L'utilisation de chitosane et/ou d'adjuvants de toxines détoxifiés de ribosylation ADP améliore les réponses immunes muqueuses anti-méningocoque et permet la déformation des réponse Th1/Th2.

Affiliated with

Also associated with

Rating

Mucosal meningococcal vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mucosal meningococcal vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mucosal meningococcal vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1423501